VIR-1388

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Cytomegalovirus (CMV)HIV (Human Immunodeficiency Virus)HIV I Infection

Phase 1

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

CompletedNCT05854381

National Institute of Allergy and Infectious Diseases (NIAID)HIV I Infection

Start: 2023-09-19End: 2025-11-19Updated: 2026-03-03

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV

Not yet recruitingNCT07801456

National Institute of Allergy and Infectious Diseases (NIAID)Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)

Start: 2026-10-15End: 2028-02-02Target: 12Updated: 2026-09-03